Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy.

American journal of physiology. Heart and circulatory physiology - 1 Feb 2021

Awinda Peter O, Watanabe Marissa, Bishaw Yemeserach, Huckabee Anna M, Agonias Keinan B, Kazmierczak Katarzyna, Szczesna-Cordary Danuta, Tanner Bertrand C W

Abstract excerpt

Morbidity and mortality associated with heart disease is a growing threat to the global population, and novel therapies are needed. Mavacamten (formerly called MYK-461) is a small molecule that binds to cardiac myosin and inhibits myosin ATPase. Mavacamten is currently in clinical trials for the treatment of obstructive hypertrophic cardiomyopathy (HCM), and it may provide benefits for treating other forms of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzylamines
Share to Calcium Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiomyopathy, Hypertrophic

Share to Enzyme Inhibitors

Share to Myocardial Contraction

Share to Myosin Light Chains

Share to Uracil

Share to Ventricular Myosins

Source

Open in PubMed Open full text

Identifiers

PMID: 33337957
DOI: 10.1152/ajpheart.00345.2020
PMCID: PMC8082789

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy.PMID 33337957Read ↗

Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations.Semantic proximity Read ↗

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.Semantic proximity Read ↗

The dilated cardiomyopathy-causing mutation ACTC E361G in cardiac muscle myofibrils specifically abolishes modulation of Ca(2+) regulation by phosphorylation of troponin I.Semantic proximity Read ↗

Cardiac contractility, motor function, and cross-bridge kinetics in N47K-RLC mutant mice.Semantic proximity Read ↗

Broad therapeutic benefit of myosin inhibition in hypertrophic cardiomyopathySemantic proximity Read ↗

The effect of cardiomyopathy mutation (R97L) in mouse cardiac troponin T on the muscle length-mediated recruitment of crossbridges is modified divergently by α- and β-myosin heavy chain.Semantic proximity Read ↗

Mouse Models of Cardiomyopathies Caused by Mutations in Troponin C.Semantic proximity Read ↗

Hypertrophic cardiomyopathy: Mutations to mechanisms to therapiesSemantic proximity Read ↗

Danicamtiv increases myosin recruitment and alters the chemomechanical cross bridge cycle in cardiac muscleSemantic proximity Read ↗

Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases.Semantic proximity Read ↗

Mutations in Troponin that cause HCM, DCM AND RCM: what can we learn about thin filament function?Semantic proximity Read ↗

Long-term mavacamten exposure reduces force and sarcomere density in a hiPSC model of hypertrophic cardiomyopathySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.